Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atigotatug/nivolumab - Bristol-Myers Squibb

Next Previous
Drug Profile

Atigotatug/nivolumab - Bristol-Myers Squibb

Alternative Names: BMS-986012+ nivolumab fixed dose combination; BMS-986012/nivolumab; BMS-986489

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; SCRI Development Innovations
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Fucosyl GM1 ganglioside inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer

Most Recent Events

  • 07 May 2025 Phase-I clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (Parenteral) (NCT06799286)
  • 11 Mar 2025 Phase-II clinical trials in Small cell lung cancer (Combination therapy) in USA (Parenteral) (NCT06773910)
  • 31 Jan 2025 Phase-III clinical trials in Small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in USA (Parenteral) (NCT06646276)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top